ViaCyte is developing islet cell replacement therapies for insulin-requiring diabetes. Our two key products in development deploy the same active component, PEC-01 cells, but with different delivery technologies, and addressing the unmet needs of different patient groups.
PEC-Direct™ being developed for the approximately 10% of T1D patients at highest risk of acute complications and death; expected to require immune suppressive medications to protect the engrafted cells.
PEC-Encap™ being developed for all insulin-requiring diabetes patients (T1D & T2D); designed to be therapeutic without the need for long-term immunosuppressive medications. PEC-Encap, while expected to be a second generation product approved after PEC-Direct, was the first embryonic stem cell-derived therapy for diabetes to reach the clinic – in the STEP ONE Trial (Safety, Tolerability, and Efficacy of PEC-Encap Combination Product in Type One Diabetes).